179 related articles for article (PubMed ID: 30631747)
1. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.
Schreiber AR; Nguyen A; Bagby SM; Arcaroli JJ; Yacob BW; Quackenbush K; Guy JL; Crowell T; Stringer B; Danaee H; Kalebic T; Messersmith WA; Pitts TM
Clin Cancer Drugs; 2018; 5(1):42-49. PubMed ID: 30631747
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-derived Xenografts.
Abu-Yousif AO; Cvet D; Gallery M; Bannerman BM; Ganno ML; Smith MD; Lai KC; Keating TA; Stringer B; Kamali A; Eng K; Koseoglu S; Zhu A; Xia CQ; Landen MS; Borland M; Robertson R; Bolleddula J; Qian MG; Fretland J; Veiby OP
Mol Cancer Ther; 2020 Oct; 19(10):2079-2088. PubMed ID: 32788205
[TBL] [Abstract][Full Text] [Related]
3. A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.
Gallery M; Zhang J; Bradley DP; Brauer P; Cvet D; Estevam J; Danaee H; Greenfield E; Li P; Manfredi M; Loke HK; Rabino C; Stringer B; Williamson M; Wyant T; Yang J; Zhu Q; Abu-Yousif A; Veiby OP
PLoS One; 2018; 13(1):e0191046. PubMed ID: 29370189
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.
Almhanna K; Prithviraj GK; Veiby P; Kalebic T
Pharmacol Ther; 2017 Feb; 170():8-13. PubMed ID: 27765652
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Catabolism of [
Bolleddula J; Shah A; Shadid M; Kamali A; Smith MD; Chowdhury SK
Drug Metab Dispos; 2020 Nov; 48(11):1239-1245. PubMed ID: 32843329
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
Almhanna K; Miron ML; Wright D; Gracian AC; Hubner RA; Van Laethem JL; López CM; Alsina M; Muñoz FL; Bendell J; Firdaus I; Messersmith W; Ye Z; Fasanmade AA; Danaee H; Kalebic T
Invest New Drugs; 2017 Apr; 35(2):235-241. PubMed ID: 28188407
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna K; Wright D; Mercade TM; Van Laethem JL; Gracian AC; Guillen-Ponce C; Faris J; Lopez CM; Hubner RA; Bendell J; Bols A; Feliu J; Starling N; Enzinger P; Mahalingham D; Messersmith W; Yang H; Fasanmade A; Danaee H; Kalebic T
Invest New Drugs; 2017 Oct; 35(5):634-641. PubMed ID: 28527133
[TBL] [Abstract][Full Text] [Related]
8. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody.
Menezes B; Khera E; Calopiz M; Smith MD; Ganno ML; Cilliers C; Abu-Yousif AO; Linderman JJ; Thurber GM
AAPS J; 2022 Oct; 24(6):107. PubMed ID: 36207468
[TBL] [Abstract][Full Text] [Related]
10. Dual-Isotope Cryoimaging Quantitative Autoradiography: Investigating Antibody-Drug Conjugate Distribution and Payload Delivery Through Imaging.
Ilovich O; Qutaish M; Hesterman JY; Orcutt K; Hoppin J; Polyak I; Seaman M; Abu-Yousif AO; Cvet D; Bradley DP
J Nucl Med; 2018 Sep; 59(9):1461-1466. PubMed ID: 29728518
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.
Nagaoka K; Bai X; Ogawa K; Dong X; Zhang S; Zhou Y; Carlson RI; Jiang ZG; Fuller S; Lebowitz MS; Ghanbari H; Wands JR
Cancer Lett; 2019 May; 449():87-98. PubMed ID: 30768955
[TBL] [Abstract][Full Text] [Related]
12. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
[TBL] [Abstract][Full Text] [Related]
14. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Kim R; Leal AD; Parikh A; Ryan DP; Wang S; Bahamon B; Gupta N; Moss A; Pye J; Miao H; Inguilizian H; Cleary JM
Cancer Chemother Pharmacol; 2023 Apr; 91(4):291-300. PubMed ID: 36738333
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
Lieu CH; Klauck PJ; Henthorn PK; Tentler JJ; Tan AC; Spreafico A; Selby HM; Britt BC; Bagby SM; Arcaroli JJ; Messersmith WA; Pitts TM; Eckhardt SG
Oncotarget; 2015 Oct; 6(33):34561-72. PubMed ID: 26439693
[TBL] [Abstract][Full Text] [Related]
16. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hara H; Sugase T; Otsuru T; Saito Y; Tsujii S; Nomura T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Eguchi H; Yamasaki M; Mori M; Doki Y; Naka T
Br J Cancer; 2020 Apr; 122(9):1333-1341. PubMed ID: 32152502
[TBL] [Abstract][Full Text] [Related]
17. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
18. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna K; Kalebic T; Cruz C; Faris JE; Ryan DP; Jung J; Wyant T; Fasanmade AA; Messersmith W; Rodon J
Clin Cancer Res; 2016 Oct; 22(20):5049-5057. PubMed ID: 27178743
[TBL] [Abstract][Full Text] [Related]
19. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.
Micel LN; Tentler JJ; Tan AC; Selby HM; Brunkow KL; Robertson KM; Davis SL; Klauck PJ; Pitts TM; Gangolli E; Fabrey R; O'Connell SM; Vincent PW; Eckhardt SG
Mol Cancer Ther; 2015 Feb; 14(2):317-25. PubMed ID: 25376610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
